Invariant NKT (iNKT) cells recognize glycolipid Ags, such as the marine sponge-derived glycosphingolipid ␣-galactosylceramide (␣GalCer) presented by the CD1d protein. In vivo activation of iNKT cells with ␣GalCer results in robust cytokine production, followed by the acquisition of an anergic phenotype. Here we have investigated mechanisms responsible for the establishment of ␣GalCer-induced iNKT cell anergy. We found that ␣GalCer-activated iNKT cells rapidly up-regulated expression of the inhibitory costimulatory receptor programmed death (PD)-1 at their cell surface, and this increased expression was retained for at least one month. Blockade of the interaction between PD-1 and its ligands, PD-L1 and PD-L2, at the time of ␣GalCer treatment prevented the induction iNKT cell anergy, but was unable to reverse established iNKT cell anergy. Consistently, injection of ␣GalCer into PD-1-deficient mice failed to induce iNKT cell anergy. However, blockade of the PD-1/PD-L pathway failed to prevent bacterial-or sulfatide-induced iNKT cell anergy, suggesting additional mechanisms of iNKT cell tolerance. Finally, we showed that blockade of PD-1/PD-L interactions enhanced the antimetastatic activities of ␣GalCer. Collectively, our findings reveal a critical role for the PD-1/PD-L costimulatory pathway in the ␣GalCer-mediated induction of iNKT cell anergy that can be targeted for the development of immunotherapies.
I nvariant NKT (iNKT)
3 cells are a unique subset of T lymphocytes that recognize glycolipid Ags in the context of the Ag-presenting glycoprotein CD1d (1) (2) (3) (4) (5) . iNKT cells express a semi-invariant TCR together with surface markers that are characteristic of the NK cell lineage (6) . iNKT cells can react with glycosphingolipids derived from Sphingomonas bacteria (7) (8) (9) , diacylglycerols from Borrelia burgdorferi (10) , the endogenous glycolipid isoglobotrihexosylceramide (11) , and the marine sponge-derived Ag ␣-galactosylceramide (␣GalCer) (12) . Glycolipid-activated iNKT cells produce copious amounts of cytokines, which endow these cells with potent immunoregulatory properties (13) . Consequently, iNKT cells have been implicated in regulating a variety of immune responses (1) (2) (3) (4) . These potent immunoregulatory properties of iNKT cells are being exploited for the development of vaccine adjuvants (14) , immunotherapy of cancer (15, 16) and prevention of autoimmune and inflammatory conditions (17) .
To develop safe and effective iNKT cell-based therapies, it is critically important to obtain a thorough understanding of the in vivo response of iNKT cells to glycolipid Ag stimulation. This issue is best understood for the prototypical iNKT cell Ag ␣GalCer. In vivo activation of iNKT cells with ␣GalCer results in dynamic changes in the iNKT cell population, which is characterized by surface TCR down-modulation, robust cytokine secretion, clonal expansion, homeostatic contraction, and acquisition of an anergic phenotype (18 -25) . iNKT cells rendered anergic in this manner failed to protect mice against the development of metastatic B16 melanomas in the lung upon restimulation with ␣GalCer (21) . Instead, ␣GalCer exacerbated B16 lung metastases in the ␣GalCer-experienced animals, raising concerns regarding the utility of repeated ␣GalCer therapy in a multidose setting (21) . These findings highlight the need for effective means to avoid the induction of iNKT cell anergy and to break anergy once it has been established.
Programmed death (PD)-1 (CD279) is a member of the CD28 family of costimulatory molecules (26, 27) . Interaction of PD-1 on T cells with its ligands, PD-L1 (B7-H1 or CD274) and PD-L2 (B7-DC or CD273), on APCs delivers inhibitory signals to T cells. PD-1 and its ligands have been implicated in the induction and maintenance of tolerance in conventional T cells in a variety of settings (26, 27) . Consistent with the role of PD-1 in regulating T cell tolerance, PD-1-deficient mice exhibit increased susceptibility to the development of autoimmunity. In the C57BL/6 background, aged PD-1-deficient mice develop glomerulonephritis and arthritis with deposition of IgG3 and C3 in the glomeruli (28) , whereas in the BALB/c background, aged knockout animals manifest cardiomyopathy due to autoantibody production against heart troponin (29, 30) . A direct role for the PD-1/PD-L pathway in the induction and maintenance of anergy in conventional CD4 ϩ and CD8 ϩ T lymphocytes has also been documented (31) (32) (33) .
We hypothesized that the PD-1/PD-L pathway plays a critical role in the induction of anergy in glycolipid-activated iNKT cells. We have found that Ab-mediated blockade of PD-1/PD-L FIGURE 1. Expression of PD-1 on iNKT cells following ␣GalCer stimulation in vivo. Mice were injected with 2 g of ␣GalCer, spleen and liver mononuclear cells were prepared at the indicated time points, and cells were stained with anti-TCR-␤-FITC, tetramer-allophycocyanin, anti-B220-PerCP, and PD- 
FIGURE 2. Expression of PD-L1
and PD-L2 on APC following ␣Gal-Cer injection in vivo. Mice were treated as in Fig. 1 and spleen cells were stained with anti-B220-PerCP, anti-CD11c-APC, and anti-PD-L1-PE, anti-PD-L2-PE or isotype control antirat IgG2a-PE. A representative of three separate experiments is shown.
interactions at the time of ␣GalCer treatment prevented the induction of iNKT cell anergy in wild-type animals. Likewise, PD-1-deficient mice were resistant to the development of ␣GalCer-induced iNKT cell anergy. Moreover, blockade of PD-1/PD-L interactions enhanced the antitumor activities of ␣GalCer in mice. However, despite its critical role in ␣GalCer-induced iNKT cell anergy, the PD-1/PD-L pathway did not appear to be required for bacterial-or Type II NKT cell-mediated anergy, suggesting multiple pathways for iNKT tolerance. These findings reveal a critical role of the PD-1/PD-L costimulatory pathway for glycolipid-mediated induction of iNKT cell anergy, with important implications for the development of iNKT cell-based therapies.
Materials and Methods

Mice
Female C57BL/6 (B6) and adult thymectomized B6 mice were purchased from The Jackson Laboratory. PD-1-deficient mice (34) on a B6 background were obtained from Dr. Tasuku Honjo (Kyoto University, Kyoto, Japan) via Dr. Megan Sikes (Transplantation Biology Research Center, Boston, MA). All animal studies were approved by the Institutional Animal Care and Use Committee of Vanderbilt University (Nashville, TN).
Reagents ␣GalCer (KRN7000) was obtained from Kirin Brewery and sulfatide was obtained from Matreya. These lipids were reconstituted in PBS containing 0.5% polysorbate-20 (Sigma-Aldrich). Biotinylated CD1d monomers were obtained from the National Institute of Allergy and Infectious Diseases Tetramer Facility and fluorescently-labeled tetrameric CD1d molecules were loaded with ␣GalCer, as described previously (35) . Anti-TCR-␤-FITC and -allophycocyanin, anti-NK1.1-PE and -allophycocyanin, antiCD11c-allophycocyanin, anti-B220-peridinin chlorophyll protein (PerCP), anti-IL-4-PE, anti-IFN-␥-FITC, and anti-CD69-FITC were obtained from BD Pharmingen. Anti-PD-1-PE, -PD-L1-PE and -PD-L2-PE were obtained from eBioscience. For blocking experiments, purified hamster anti-mouse PD-1 (J43 (36)) or control hamster Abs, rat anti-mouse PD-L1 (MIH5 (31), Riken Cell Bank) and rat anti-mouse PD-L2 (TY25 (37)) or control rat Abs were used.
Flow cytometry
Single-cell suspensions of the spleen and liver were prepared and stained with fluorescently-labeled mAbs, as described previously (38) . In all experiments, dead cells were excluded from the analysis by electronic gating. The iNKT cell population was identified as B220 Ϫ TCR-␤ ϩ tetramer ϩ cells. For analysis of intracellular cytokines produced by iNKT in vivo, mice were injected with ␣GalCer or vehicle, killed 1 h later, and splenocytes or liver mononuclear cells were cultured in Golgi Plug (BD Pharmingen) for an additional 2 h. For measurement of intracellular IFN-␥ levels of NK cells, mice were injected with ␣GalCer or vehicle, killed 6 h later, and splenocytes were cultured in Golgi Plug for an additional 2 h. Intracellular cytokine staining was performed with Cytofix/Cytoperm reagents (BD Pharmingen) according to the manufacturer's protocol. For staining of dendritic cells (DC), Fc receptors were first blocked by addition of anti-CD16/32 Abs (BD Pharmingen), and DC were identified on the basis of high CD11c expression. Flow cytometry was performed using a FACSCalibur instrument (BD Pharmingen), and the acquired data were analyzed using FlowJo software (Tree Star).
Measurement of iNKT cell anergy
For evaluation of ␣GalCer-induced iNKT cell anergy, mice were injected i.p. with 2 g ␣GalCer in 200 l PBS containing 0.025% polysorbate-20 (vehicle) as described previously (21) . Blocking Abs directed against PD-1, its ligands, or control Abs were administered at times indicated in the figures. Mice were analyzed around 1 mo after the initial ␣GalCer injection for the measurement of iNKT cell recall responses ex vivo or in vivo. For measurement of in vitro responses, mice were killed and spleen cell suspensions were plated in U-bottom 96-well plates at 2 ϫ 10 5 cells per well in RPMI 1640 medium containing 10% FCS (R-10) in the presence of titrated doses of ␣GalCer or vehicle. For proliferation assays, 1 Ci of [ 3 H]thymidine (PerkinElmer) was added to the wells after 60 h of culture, and cells were cultured for an additional 12 h. Cells were then harvested, and uptake of radioactivity was measured. For measurement of cytokine secretion, supernatants were harvested after 60 h of culture, and cytokine levels were evaluated by ELISA. For in vivo recall responses, the mice were reinjected with 2 g of ␣GalCer followed by evaluation of intracellular cytokine expression by iNKT cells at 1 h, IFN-␥ production and cytotoxicity by NK cells at 6 h, serum IFN-␥ production at 1 day and in vivo expansion at 3 days. For evaluation of bacteria-induced iNKT cell anergy, mice were injected i.v. with heat-killed E. coli (ATCC catalog no. 25922) (0.5 ϫ 10 9 CFU in 200 l PBS) as described (39) . Mice were tested for ex vivo and in vivo responses to ␣GalCer stimulation 3 weeks later. For evaluation of sulfatide-induced iNKT cell anergy, mice were injected i.p. with 20 g sulfatide and analyzed for ex vivo responses to ␣GalCer 24 h later as described (40) , or injected with ␣GalCer for evaluation of iNKT cell proliferation and IFN-␥ production as described above.
ELISA
A standard sandwich ELISA was performed to measure mouse-IFN-␥ and -IL-4 levels. IFN-␥-and IL-4-paired Abs and cytokine standards were obtained from BD Pharmingen. For detection, streptavidin-HRP conjugate (Zymed Laboratories) was used, and the color was developed with the substrate 3,3Ј,5,5Ј-tetramethylbenzidine (DAKO) in the presence of H 2 O 2 .
CFSE dilution analysis
Liver mononuclear cells were labeled with 5 mM CFSE (Invitrogen) for 10 min at 37°C in PBS containing 0.1% BSA and washed twice with complete RPMI 1640 medium. Labeled cells (3 ϫ 10 5 cells/well) were then stimulated with ␣GalCer for 96 h in complete RPMI 1640. At the end of the culture, cells were harvested, stained with anti-TCR-␤ and CD1d-tetramers, and analyzed by flow cytometry.
Determination of B16 melanoma lung metastases
Mice were injected i.v. with 5 ϫ 10 5 B16 melanoma cells suspended in PBS. Mice were treated with ␣GalCer or vehicle at 0, 3, and 7 days. In some experiments, ␣GalCer was injected at 5, 8, and 12 days after melanoma injection. After 15-17 days of challenge with melanoma cells, mice were killed, lungs were removed, and the number of metastatic nodules was counted as described previously (21, 24) .
NK cell cytotoxicity assay
NK cell cytotoxicity was evaluated against the NK cell target cell line YAC-1, in a standard 51 Cr release assay. Data are presented as the percent specific lysis, which was calculated as follows: 100 ϫ ((experimental release Ϫ spontaneous release)/(maximum release Ϫ spontaneous release)).
Statistics
Statistical significance between multiple groups was determined by application of ANOVA followed by Bonferroni posthoc test. The samples were first subjected to Kolmogorov-Smirnov normality test with Dallal-Wilkinson-Lillie for p-value. When samples did not follow normal distribution, Kruskal-Wallis followed by Dunn's posthoc test was used instead. A pvalue of less than 0.05 was considered significant for the multiple comparison tests. All the statistical analyses were performed using Graphpad Prism software.
Results ␣GalCer treatment preferentially up-regulates PD-1 on iNKT cells
Consistent with its expression in conventional T cells (36) , resting iNKT cells expressed very low levels of PD-1 (Fig. 1) . However, ␣GalCer treatment resulted in the rapid induction of PD-1 on iNKT cells in liver and spleen (Fig. 1) . Profound PD-1 induction was detected within 12 h of ␣GalCer treatment and its expression was maintained at high levels during the expansion (day 3) and contraction phases (days 7-15) of the iNKT cell population. Interestingly, PD-1 expression on iNKT cells was maintained during the anergic phase of ␣GalCer-experienced iNKT cells, and at least up to 30 days after the initial ␣GalCer treatment. Similar results were obtained in thymectomized animals ( Supplementary Fig. 1 ), 4 indicating that the induction and maintenance of PD-1 expression on iNKT cells was thymus-independent. Furthermore, similar induction of PD-1 expression following ␣GalCer treatment was not detected on conventional T cells (Fig. 1) , suggesting that its expression was specific to iNKT cells. Expression of CTLA-4, another member of the CD28 family of costimulatory molecules that delivers inhibitory signals to T cells (41) , remained largely unaltered on iNKT cells after ␣GalCer treatment (Supplementary Fig. 2 ).
␣GalCer treatment transiently induces the expression of PD-1 ligands on APCs
Because PD-1 interacts with PD-L1 and PD-L2 on APC (26, 27) , we investigated the expression profiles of PD-L1 and PD-L2 on DC and B cells. Consistent with prior studies (37, 42) , DC and B cells constitutively expressed PD-L1 but expressed very low levels of PD-L2 (Fig. 2) . Upon treatment with ␣GalCer, PD-L1 became up-regulated on both types of APC between 12 h and 3 days but returned to preinjection levels by 7 days. ␣GalCer similarly induced a transient expression of PD-L2 on DC, whereas its expression of B cells remained unaltered. Thus, activation of iNKT cells by ␣GalCer resulted in transient induction of PD-1 ligands on DC and B cells.
Blockade of PD-1/PD-L interactions prevents the induction of iNKT cell anergy mediated by ␣GalCer
To investigate the role of the PD-1/PD-L pathway in the induction and maintenance of iNKT cell anergy, we tested the effects of PD-1/PD-L blockade on the development of iNKT cell anergy. For this purpose, we used anti-PD-1 blocking Abs or a combination of blocking Abs directed against PD-L1 and PD-L2. In the first set of experiments, mice were treated with blocking or control Abs every 3-4 days after ␣GalCer injection for a period of one month (Fig.  3A) . iNKT cells were then restimulated either ex vivo or in vivo with ␣GalCer and iNKT cell proliferative and cytokine responses were measured (Fig. 3, B and C) . Consistent with prior results, splenocytes from vehicle-treated mice proliferated and produced cytokines in response to ␣GalCer stimulation ex vivo, whereas splenocytes from mice treated with ␣GalCer or with ␣GalCer and control Ab demonstrated a blunted response to ex vivo restimulation with ␣GalCer. In sharp contrast, splenocytes from mice treated with ␣GalCer and anti-PD-L1/L2 Abs retained their capacity to respond to the subsequent ␣GalCer stimulation. Nevertheless, this abrogation of iNKT cell anergy was not complete. A similar but less drastic effect was observed for mice treated with ␣GalCer and anti-PD-1 Abs, likely because the anti-PD-1 Ab used is not as effective in blocking PD-1/PD-L interactions (36, 43, 44) . Similar results were obtained when the secondary response of iNKT cells to ␣GalCer was investigated in vivo. iNKT cells from mice treated with vehicle expanded profoundly in response to in vivo injection with ␣GalCer, whereas mice treated with ␣GalCer in the absence or presence of control Ab were resistant to ␣Gal-Cer-induced expansion. However, iNKT cells from mice treated with ␣GalCer and anti-PD-L1/L2 Abs expanded substantially in response to ␣GalCer re-injection. Consistent with the in vitro studies, anti-PD-1 Abs had little effect on the capacity of ␣GalCer-experienced iNKT cells to respond to the secondary stimulation with this Ag.
Next, we determined whether the PD-1/PD-L pathway was critical for the induction and/or maintenance of iNKT cell anergy. When Ab treatment was initiated 10 days after the initial ␣GalCer injection, iNKT cells retained their anergic phenotype (Fig. 4) , suggesting that the PD-1/PD-L pathway was dispensable for maintaining iNKT cell anergy once it had been established. Consistent with this finding, treatment of splenocyte cultures from ␣GalCer-experienced mice with anti-PD-L1/L2 Abs was unable to overcome iNKT cell anergy (data not shown). In sharp contrast, Ab treatment during the first week following the initial ␣GalCer injection (treatment at days 0, 3, and 7) rendered iNKT cells fully reactive to the secondary stimulation with ␣GalCer (Fig. 5) . Interestingly, this Ab treatment regimen did not impact PD-1 expression on iNKT cells during the course of the experiment (data not shown), suggesting that the rescue of iNKT cell function was not due to a blockade in PD-1 induction.
Collectively, our results indicated a critical role for PD-1/ PD-L interactions in the induction of iNKT cell anergy, but that disruption of these interactions did not reverse already established anergy.
Blockade of PD-1/PD-L interactions during initial ␣GalCer treatment restores the antimetastatic activities of ␣GalCer-activated iNKT cells
␣GalCer exhibits potent antimetastatic activities in mice (1) . We have previously shown that the anergic phenotype of iNKT cells has a profound impact on the therapeutic activities of ␣GalCer, resulting in exacerbation of cancer metastasis (21), thus raising concerns regarding the utility of repeated ␣GalCer treatment during cancer therapy. We therefore tested the effects of PD-1/PD-L blockade during the initial ␣GalCer treatment on the subsequent capacity of ␣GalCer to protect mice against B16 tumor metastases. Mice were treated with ␣GalCer in the presence or absence of PD-1/PD-L blockade, and one month after the primary ␣GalCer injection, mice were challenged with B16 melanoma cells and treated with ␣GalCer. Consistent with our prior studies (21), we found that ␣GalCer was effective in clearing tumors from vehicletreated mice but exacerbated tumor development in ␣GalCer-experienced mice (Fig. 6) . In sharp contrast, iNKT cells from mice treated with anti-PD-L1/L2 Abs at the time of primary ␣GalCer injection retained their capacity to clear B16 tumor cells. Because the anti-metastatic activities of ␣GalCer involve IFN-␥ secretion and NK cell transactivation (45, 46), we also investigated whether 4 The online version of this article contains supplemental material. PD-1/PD-L blockade was able to restore these aspects of iNKT cell function. Results showed that iNKT cells from mice previously treated with ␣GalCer in the presence of anti-PD-L1/L2 Abs, upon re-injection with ␣GalCer, were able to induce serum IFN-␥ levels and transactivate NK cells to produce IFN-␥ and exhibit cytotoxicity against YAC-1 target cells (Supplementary Fig. 3 ). 4 
PD-1-deficient mice are resistant to ␣GalCer-induced iNKT cell anergy
To further define the role of PD-1 in the induction of iNKT cell anergy by ␣GalCer, we used PD-1-deficient mice (34) . These animals displayed a modest reduction in iNKT cell numbers in spleen and liver as compared with wild-type mice (Fig. 7A ) and iNKT cells from these animals exhibited a modestly increased response to ␣GalCer stimulation (Fig. 7, A-C, and data not shown) . To assay iNKT cell anergy, we injected PD-1-deficient and wild-type control mice with vehicle or ␣GalCer, and one month later we rechallenged mice in vivo with ␣GalCer followed by evaluation of iNKT cell expansion and cytokine production. Unlike iNKT cells from ␣GalCer-treated wild-type mice, iNKT cells from ␣GalCer-treated PD-1-deficient mice responded robustly to ␣GalCer restimulation, with respect to their capacity to expand (Fig. 7, A and B) and produce cytokines (Fig. 7C) . Nevertheless, our data suggested that ␣GalCer-treated PD-1-deficient mice still had a modest reduction in their response to ␣Gal-Cer rechallenge (Fig. 7, A-C) , suggesting that additional pathways contribute to the induction of iNKT cell anergy. Next, we determined the effects of ␣GalCer pretreatment on the antimetastatic activities of iNKT cells in PD-1-deficient mice. Similar to wild-type animals, ␣GalCer treatment protected naive PD-1-deficient mice against B16 tumor metastases (Fig. 7D) . However, in ␣GalCer pretreated animals, ␣GalCer retained its therapeutic activities against B16 melanoma cells in PD-1-deficient mice, but exacerbated metastasis formation in wild-type mice. Protection against the development of tumor metastases in PD-1-deficient animals correlated with restored IFN-␥ levels in the serum and the capacity of NK cells to synthesize intracellular IFN-␥ and lyse YAC-1 target cells ( Supplementary Fig. 4 ). 4 
PD-1/PD-L blockade enhances the antimetastatic activities of ␣GalCer
We tested the therapeutic potential of combined treatment with ␣GalCer and PD-1/PD-L blockade against metastatic tumors. In the first set of experiments, mice were injected with B16 tumor cells and treated with ␣GalCer and blocking Abs at 0, 3, and 7 days, followed by evaluation of tumor metastases at 15 days. Results demonstrated that blockade of PD-1/PD-L interactions enhanced the antimetastatic activities of ␣GalCer (Fig. 8A ). In contrast, treatment with the blocking Abs in the absence of ␣GalCer did not affect tumor development. In the second set of experiments, we initiated combined ␣GalCer and Ab treatment 5 days after B16 tumor challenge, mimicking a treatment regimen of established tumors. Again, anti-PD-L1/L2 Abs (but not anti-PD-1 antibodies) enhanced the antimetastatic activities of ␣GalCer (Fig. 8B) . Consistent with these findings, we found that combined treatment with ␣GalCer and PD-1/PD-L blockade enhanced serum IFN-␥ levels (Fig. 8C) .
PD-1/PD-L interactions are not required for induction of iNKT cell anergy mediated by bacteria or sulfatide
It has recently been demonstrated that multiple bacterial microorganisms can induce anergy in iNKT cells (39, 47, 48) . We therefore tested the role of the PD-1/PD-L pathway in the induction of anergy by heat-inactivated Escherichia coli. E. coli microorganisms induced a sustained up-regulation of PD-1 expression on iNKT cells (Fig. 9A) , although this was much less pronounced than the levels of PD-1 induced by ␣GalCer (compare Fig. 9A with Fig.   1 ). Further, these organisms retained their capacity to induce iNKT cell anergy in PD-1-deficient mice (Fig. 9B) .
In recent studies, we have shown that sulfatide, a ligand for a subset of CD1d-restricted NKT cells (Type II NKT cells) expressing diverse TCRs, can also induce hyporesponsiveness in iNKT cells (40) . Again, similar to bacteria-induced iNKT cell anergy, blockade of PD-1/PD-L interactions was unable to prevent the induction of iNKT cell anergy mediated by sulfatide (Fig. 9, C and D) .
Discussion
Anergy is a physiological state induced by Ag in T lymphocytes that is characterized by impaired proliferative and cytokine responses to subsequent exposure to cognate Ag (33, 49) . The induction of anergy plays a critical role in maintaining self-tolerance and its loss can result in autoimmunity. Understanding the mechanisms by which anergy is induced is important because it permits investigators to manipulate T cell responses. Although anergy in conventional T cells is induced only in certain conditions, such as during situations of incomplete or chronic T cell stimulation (49, 50) , anergy appears to be the physiological response of iNKT cells to cognate glycolipid Ags (21) (22) (23) . Expression of a semi-invariant TCR by iNKT cells permits the host to generate an effective response to glycolipid Ags. Because of their innate characteristics, the response of iNKT cells is fast and robust, with production of cytokines that are potentially toxic to the host. For example, ␣Gal-Cer can induce liver toxicity in mice and even death in older animals (51) . As such, the activity of iNKT cells requires tight regulation, to avoid exuberant inflammation and its associated pathology. Consequently, anergy might be a means to avoid such adverse outcomes of iNKT cell activation. Although iNKT cell anergy might be beneficial to the host under normal conditions, it poses a problem with regard to the therapeutic activities of iNKT cells. Our finding that the PD-1/PD-L pathway plays a critical role in mediating ␣GalCer-induced iNKT cell anergy opens up the possibility to manipulate iNKT cell function during glycolipid therapy. Our findings are in general agreement with a recent study (52) , published after submission of the present manuscript, demonstrating a critical role for the PD-1/PD-L pathway in ␣GalCer-induced iNKT cell anergy. Prior studies have provided evidence that PD-1/PD-L interactions contribute not only to the induction but also to maintenance of anergy in conventional T cells, at least in the systems tested (31) (32) (33) . In addition, blockade of PD-1/PD-L interactions was able to reverse the exhausted phenotype of CD8 ϩ and CD4 ϩ lymphocytes during chronic infections (44, 53, 54) . We found that blockade of PD-1/PD-L interactions at the time of ␣GalCer treatment was able to prevent induction of iNKT cell anergy, but had little effect on the anergic phenotype once it was established. This outcome was surprising, as anergic iNKT cells expressed high surface levels of PD-1 (Fig. 1) . Thus, other intercellular interactions might play a role in maintaining iNKT cell anergy. Although CTLA-4 has been implicated in the induction of anergy in conventional CD4 ϩ T cells (55, 56) , it was not induced at significant levels on ␣GalCer-activated iNKT cells (Supplementary Fig. 2) . 4 In addition, we found that ␣GalCer was able to induce iNKT cell anergy in mice with a combined deficiency in the ligands of CTLA-4 (B7-1 and B7-2) (Supplementary Fig. 5B) , 4 arguing against a role for CTLA-4 in ␣GalCer-induced iNKT cell anergy.
Recent studies have shown that PD-L1 can bind with B7-1 and that this interaction delivers an inhibitory signal to T cells and inhibits proliferation (57) . Therefore, it is possible that the effects of PD-L1 on iNKT cell anergy were mediated, at least in part, through its interaction with B7-1. However, our finding that PD-1-deficient mice are resistant to induction of iNKT cell anergy by ␣GalCer argues for a critical role of PD-1. In addition, we found that iNKT cells from B7-1-deficient mice can be rendered anergic following treatment of these animals with ␣GalCer (Supplementary Fig. 5A ). Based on these findings, we favor the notion that interactions between PD-1 and its ligands PD-L1 and PD-L2 are critical for the induction of iNKT cell anergy.
We found that Abs directed against PD-L1 and PD-L2 were more effective than Abs against PD-1 to prevent anergy induction ( Fig. 3 and 5) . One likely reason is that the anti-PD-1 Ab used is not as effective in blocking PD-1/PD-L interactions (36, 43, 44) . The effects of the anti-PD-1 Ab on anergy induction also depended on the parameter investigated, with few effects observed when iNKT cell anergy was analyzed by total proliferative and cytokine responses in spleen cell cultures (Figs. 3B and 5B) or by investigating iNKT cell expansion in vivo (Figs. 3C and 5C ), but more profound effects were observed when investigating intracellular cytokine production by iNKT cells (Fig. 5, D and E) , serum IFN-␥ production ( Supplementary Fig. 3A ) 4 or intracellular IFN-␥ production by NK cells (Supplementary Fig. 3B ). 4 Although our data clearly demonstrate a critical role for the PD-1/PD-L pathway in anergy induction, blockade of this interaction, or PD-1-deficiency, did not completely overcome iNKT cell hyporesponsiveness induced by ␣GalCer (Figs. 3, 5, and 7) . These findings suggest that additional mechanisms contribute to ␣GalCer-induced iNKT cell anergy.
In addition to ␣GalCer, several other conditions can result in the induction of iNKT cell hyporesponsiveness. Multiple bacterial microorganisms and microbial products induce a hyporesponsive phenotype in iNKT cells (39, 47, 48) . Although some bacteria contain glycolipid Ags that can activate iNKT cells, most bacteria activate these cells in an indirect manner, via microbial products that can activate TLR on DC (58, 59) . DC activated in this manner elaborate cytokines such as IL-12 and IL-18 that can activate iNKT cells. In some, but not all cases, this mode of iNKT cell activation requires CD1d expression on the DC. Sulfatide, a ligand of a subset of CD1d-restricted T cells referred to as Type II NKT cells that express more diverse TCR than iNKT cells, also induces iNKT cell anergy, in a manner that requires interactions with DC (40) . The phenotype of iNKT cells rendered hyporesponsive by bacterial microorganisms or sulfatide bears many similarities with iNKT cells that became anergic in response to ␣GalCer. It was therefore surprising that the PD-1/PD-L pathway did not appear to be critical for the induction of iNKT cell hyporesponsiveness by E. coli bacteria or sulfatide (Fig. 9) . Interestingly, we have previously shown that the induction of iNKT cell hyporesponsiveness by E. coli or sulfatide requires IL-12 production whereas IL-12 is dispensable for ␣GalCer-induced iNKT cell anergy (39, 40) . These findings suggest multiple pathways and mechanisms for the induction of peripheral iNKT cell tolerance.
iNKT cells hold substantial promise for the development of immunotherapies (45) . We have previously shown that iNKT cell anergy induced by ␣GalCer or bacterial microorganisms impairs the therapeutic activities of iNKT cells against metastatic cancers (21, 39) . Here we have shown that blockade of PD-1/PD-L interactions at the time of ␣GalCer treatment prevents the induction of iNKT cell anergy, preserving the therapeutic activities of these cells against B16 tumors (Fig. 6) . Likewise, iNKT cells in ␣Gal-Cer-treated PD-1-deficient mice retained their antimetastatic activities (Fig. 7D) . In addition to preventing the induction of iNKT cell anergy, we further found that PD-1/PD-L blockade enhanced the antimetastatic activities of ␣GalCer (Fig. 8) . Therefore, our findings suggest that combined therapy with ␣GalCer and PD-1/ PD-L blockade is superior to ␣GalCer therapy alone. Furthermore, because this protocol prevents the induction of iNKT cell anergy, it should be effective when used repeatedly, such as during disease relapse.
